Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1992;70(1):93-103.

Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya

Affiliations
Comparative Study

Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya

P W Kok et al. Bull World Health Organ. 1992.

Abstract

A study was carried out in a rural community in Kenya to compare the humoral and intestinal immunity provided by three doses of oral poliovirus vaccine (OPV) and two or three doses of enhanced-potency inactivated poliovirus vaccine (IPV). The immunization series was started at 8-12 weeks of age and the interval between doses was 2 months. In children with low levels of maternal antibodies (i.e., those most at risk), the first dose of either vaccine stimulated antibody response. Children with high levels of maternal antibodies responded to the first dose of OPV, but not to that of IPV. Subsequent doses led to increases in the mean antibody titres with both vaccines. After three doses of OPV, the proportion of children with antibody titres of greater than or equal to 1:8 was 92% for type 1 virus, 98% for type 2, and 90% for type 3. After two doses of IPV the proportion of children with antibody titres of greater than or equal to 1:8 was 94%, 88%, and 97% for type 1, type 2, and type 3, respectively; after three doses of IPV, 100% of children had antibodies greater than or equal to 1:8 for types 1 and 3, and 98% for type 2. Intestinal immunity was tested with a challenge dose of type 1 OPV, but the dose used was too small to detect a significant difference between the vaccines.

PubMed Disclaimer

References

    1. Infect Dis Clin North Am. 1990 Mar;4(1):75-83 - PubMed
    1. J Infect Dis. 1990 Dec;162(6):1291-7 - PubMed
    1. Lancet. 1990 May 19;335(8699):1192-5; discussion 1196-8 - PubMed
    1. Lancet. 1991 Sep 21;338(8769):715-20 - PubMed
    1. Lancet. 1988 Feb 27;1(8583):429-33 - PubMed

Publication types

LinkOut - more resources